Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control. Characterizing binding properties of complex biomolecules is a critical step. Biophysical data combined with functional assays are needed to predict efficacy and potency, optimize drug delivery, assess critical quality attributes, and improve biologics drug design.

Traditional approaches have limited use in a complex biological environment with multiple interactions. Our speakers have developed and implemented more sensitive and higher throughput technologies:

In this webinar our speakers show:

• A method of testing the interaction of a lead biosimilar antibody candidate versus a commercially available antibody
• The development of a more sensitive assay to determine the level of binding activity and for QC lot release
• An expression platform to aid early-stage clone screening and protein characterization
• A higher-throughput platform to streamline cell line development and characterization workflows
   

Speakers: 

• Ron Morena, Manager in Analytical Bioassay – Tanvex CDMO
• Dr. Neha Mishra, Senior Scientist, BioProduction - Revvity

For research use only. Not for use in diagnostic procedures.